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reduce mortality in patients with advanced chronic heart
failure (CHF) and depressed ejection fraction (EF) [1–
3]. However, compared with participants in clinical tri-
als, patients in clinical practice are generally older, more
often female, and are more likely to have comorbid
conditions [4, 5]. Furthermore, approximately 30–50%
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of patients have a normal or nearly normal EF [6]. In




-blockers is frequently pre-
scribed at doses lower than those investigated in clinical
trials, probably attributable to concern about its tolera-





blocker medication in real-world practice of advanced
CHF remains uncertain.
Findings in patients with moderate to advanced CHF
and a broad range of EF are inconclusive. The





reduces the risk of death in patients older than 70 years,
regardless of EF. However, the risk reduction is lower
compared with younger patients with depressed EF [9].





-blocker is not a significant predictor of mortality in
patients older than 75 years, irrespective of EF [10]. In









65 years) with a
broad range of EF have reported a benefit on mortality





reduction) [7, 11]. This leaves the question to what




-blockers is modified by the
age of the patient.





-blocker prescription at discharge and mortal-
ity in a daily practice cohort of patients with advanced
CHF, and second, whether this association is modified






Patients were selected at the Cardiology Department of
Rijnland General hospital, Leiderdorp, the Netherlands,
between January 2000 and July 2004. Patients admitted
to hospital with CHF New York Heart Association




45 years, were included
in the study. Referral of patients for admission was made
by general practitioners, other units of the hospital or
the outpatient clinic. HF with reduced systolic function
was diagnosed on the basis of clinical presentation
(signs and symptoms of HF) and presence of systolic




40%). HF with preserved systolic function was defined
based on clinical symptoms, radiographic evidence of




40% [12]. EF was assessed by ‘eyeball’
estimate. All patients gave informed consent for the
study, which was approved by the local medical ethics
committee.
 
Medication and clinical variables
 
Demographic characteristics, clinical data and medica-
tion prescribed at discharge were collected prospec-





prescribed in multiple drug combinations, the following
classes of medication were considered for adjustment:
angiotensin-converting enzyme inhibitors (ACEI),
angiotensin receptor blockers (ARB), aldosterone
antagonists, loop diuretics, digitalis, calcium-channel











and loop diuretics were classified into one of the three
mutually exclusive groups: not dispensed, low or high
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50% of the dose used in RCTs (Table 1) [7]. After
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Clinical characteristics considered as candidate vari-
ables for adjustment included: age, gender, history of
hypertension or myocardial infarction (MI), severity of
CHF assessed by NYHA class and EF, heart rate, mean
arterial pressure, renal function assessed by glomerular
filtration rate (GFR), haemoglobin levels and comorbid-
ities such as diabetes, chronic obstructive pulmonary
disease (COPD), stroke or atrial fibrillation (AF). GFR
was calculated using the Cockroft–Gault equation:
[(140 − age in years) × (body weight in kg)]/serum cre-
atinine in µmol l−1. In men, the value is multiplied by
1.25 [13]. Mean arterial pressure was calculated as the
sum of 2/3 diastolic blood pressure and 1/3 systolic
blood pressure. Anaemia was defined as haemoglobin
<8.5 mmol l−1 for men and <7.5 mmol l−1 for women.
Haemoglobin levels were missing in 41 patients (6%)
and the values were obtained by mean imputation.
Forty-nine patients (7%) who missed EF at discharge
and 17 patients (3%) transferred to other departments
were excluded from the analysis.
Outcomes
Clinical outcome included all-cause mortality. Follow-
up was calculated from the date of discharge until Sep-
tember 2004. Deaths during follow-up were obtained
from hospital records, next-of-kin review or by
telephone.
Statistical analysis
Differences among patient subgroups were evaluated by
using ANOVA or χ2 test, as appropriate.
To assess the association between β-blocker prescrip-
tion and mortality during follow-up multivariate Cox
proportional hazard models was used. We controlled for
baseline characteristics that had an independent associ-
ation with mortality (P < 0.3) and for important risk
variables identified in previous studies (EF and NYHA
class). To minimize selection bias, we also adjusted for
propensity score of β-blocker use [14]. For each patient,
a propensity score indicating the likelihood of having
prescribed a β-blocker was calculated by forward logis-
tic regression. Baseline characteristics that had an inde-
pendent association with prescription of a β-blocker
(P < 0.3) were included in the multivariate logistic
model. Goodness-of-fit of the propensity score was eval-
uated by the Hosmer–Lemeshow test and discrimination
by the c statistic. Linearity of continuous variables was
checked, resulting in only mean arterial pressure being
included as a continuous variable in the model.
To assess whether there is effect modification by age,
a secondary analysis including interaction terms was
performed. The risk of death was presented by hazard
ratios (HR) with 95% confidence intervals (95% CI). All
reported probabilities were two-tailed, and a P-value
<0.05 was considered statistically significant. Data were




The total cohort at discharge included 625 patients;
approximately half were female (Table 2). Patients were
elderly, with a mean age of 76 years (median 78 years,
90% reference range 56–90). Nearly 64% were in
NYHA III and 36% in NYHA IV. The mean EF was
42 ± 16% (45% having EF >40%). Approximately 44%
had a history of MI and 45% had a history of hyperten-
sion. The prevalence of diabetes, AF and COPD was
30%, 40% and 30%, respectively. About half of the
patients  had  severe  renal  dysfunction  (GFR  <40  ml
min−1).
Medication at discharge
Overall, 308 (49%) patients had a β-blocker prescribed
at discharge, with 140 (46%) receiving low-dose therapy
and 168 (54%) high-dose therapy (Table 2). Patients
receiving high doses of β-blockers were more often
younger, female, had a higher mean arterial pressure and
a higher prevalence of preserved EF. Conversely, they
had a lower prevalence of COPD, low sodium serum
levels and renal dysfunction. Patients on high-dose β-
blockers received less often high doses of loop diuretics
and spironolactone. Users of β-blockers received more
nitrates and aspirin, and less antiarrhythmics, digoxin
and coumarins than non-users.
Mortality outcome
The mean duration of follow-up was 22 (±15) months.
Death (all causes) occurred in 54 (17.5%) patients on a
β-blocker and 117 (37%) patients without a β-blocker.
Overall, 171 (27%) patients died during a median
follow-up of 8 months.
In univariate analysis, the following variables were
associated with a higher risk of death: older age, male
gender, lower mean arterial pressure, COPD, lower
sodium serum, lower GFR, nonprescription of a β-
blocker (either low or high dose) or aspirin, and pre-
scription of loop diuretics (high dose), spironolactone
(high dose), antiarrhythmics and digoxin (Table 3).
Propensity score analysis
Patients were more likely to be prescribed β-blockers if
they were younger, had higher systolic blood pressure,
or had a nitrate or aspirin prescribed. In contrast, β-
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blockers were less likely to be prescribed if patients had
COPD or had an antiarrhythmic or digoxin prescribed.
The model had a good discriminatory power and good
fit (c-statistics, 0.75; overall goodness-of-fit Hosmer–
Lemeshow test; χ2 = 7.1, P = 0.5).
Multivariate analysis
After adjustment for clinical variables and propensity
scores, β-blocker use remained associated with a 45%
relative reduction in the risk of death (HR 0.55, 95% CI
0.39, 0.78) (Table 4). The relative risk reduction was
similar with the prescription of low or high doses of
β-blockers, 42% and 49%, respectively (HR 0.58, 95%
CI 0.38, 0.88, P = 0.01; HR 0.51, 95% CI 0.31, 0.82,
P = 0.006) (results not shown). The absolute risk reduc-
tion (ARR) (derived from Cox survival curves) was as
follows: 5% at 6 months, 8% at 1 year and 10% at
2 years. The number needed to treat (NNT = 1/ARR) to
Table 2















Age, years, mean (SD) 76 (10) 77 (9) 77 (11) 75 (10) 0.03
>75 years (%) 59 64 55 54 0.03
Gender (% female) 47 43 48 53 0.05
History of myocardial infarction (%) 44 43 44 45 0.7
History of hypertension (%) 45 38 49 57 <0.001
NYHA (% IV) 36 38 36 32 0.2
LVEF, mean (SD) 42 (16) 42 (16) 38 (15) 47 (15) <0.001
>40% (%) 45 45 37 56 0.08
Heart rate >100 beats min−1 (%) 45.4 45.0 48.6 42.9 0.8
Mean arterial pressure, mmHg (SD) 102 (22) 97 (20) 104 (22) 108 (25) <0.001
Diabetes (%) 29 27 31 30 0.5
Atrial fibrillation (%) 39 42 36 36 0.1
COPD (%) 29 36 24 19 <0.001
Sodium serum <137 mmol l−1 (%) 19 22 19 14 0.06
Haemoglobin <8.5/7.5 mmol l−1 (%) 44 46 43 42 0.3
GFR <40 ml min−1 (%) 48 49 51 43 0.2
Medication at discharge (%)
ACE inhibitors 0.8
Low dose 37 39 40 26.7
High dose 33 29 36 35
ARB 11 11 8 16 0.2
Loop diuretic 0.05
Low dose 61 57 68 61
High dose 27 30 25 22
Spironolactone 0.03
Low dose 28 27 31 27
High dose 10 13 9 6
Digoxin 23 29 16 17 <0.001
Antiarrhythmic 24 34 13 16 <0.001
Nitrates 50 42 55 61 <0.001
Calcium-channel blockers 14 14 8 20 0.2
Coumarin 56 62 54 47 0.001
Aspirin 29 22 32 42 <0.001
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; COPD, chronic obstructive pulmonary diseasse; GFR,
glomerular filtration rate; ARB, angiotensin receptor blocker. A low dose of angiotensin-converting enzyme inhibitor andβ-blocker
is defined as < 50% of the target dose attained in randomized clinical trials. A low dose of loop diuretics is defined as furosemide
≤80 mg, bumetanide ≤2 mg. A low dose of spironolactone is defined as ≤25 mg.
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avoid one death was as follows: 20 patients for
6 months, 12 patients for 1 year and 10 patients for
2 years.
However, in the secondary analysis for interaction
effects, we found a different effect of β-blocker medi-
cation in patients younger and older than 75 years
(P = 0.006). No other interaction remained significant in
the final model. In patients aged ≤75 years prescription
of a β-blocker was associated with a 71% relative risk
reduction, while in patients >75 years it was associated
with 21% relative risk reduction (Table 4). For both age
groups, a similar effect was observed with prescription
of low- or high-dose β-blocker. Loop diuretics in high
dose were significantly associated with a twofold
increase in the risk of death. Prescription of spironolac-
tone (high dose) was associated with about 30% reduc-
tion in the risk of death (nonsignificant). Clinical
variables significantly associated with an increased risk
of death were male gender, lower GFR and lower mean
arterial pressure (Table 4).
In our study population, patients >75 years old
comprised more women, had significantly higher EF,
more AF, less MI, lower GFR and lower haemoglobin
concentrations, compared with patients <75 years old
Table 3








Age, years, mean (SD) 77 (10) 78 (9) 1.02 (1.01, 1.04) 0.02
>75 years (%) 60 65 1.3 (0.9, 1.9) 0.1
Gender (% female) 50 40 0.7 (0.5, 0.9) 0.02
History of hypertension (%) 46 40 0.8 (0.6, 1.2) 0.2
NYHA (% IV) 35 42 1.1 (0.8, 1.6)) 0.5
LVEF, mean (SD) 43 (16) 41 (18) 0.9 (0.98, 1.01) 0.4
>40% (%) 46 42 0.9 (0.6, 1.2) 0.4
Mean arterial pressure, mmHg (SD) 103 (22) 96 (21) 0.9 (0.97, 0.99) <0.001
Atrial fibrillation (%) 40 36 0.9 (0.6, 1.3) 0.5
COPD (%) 27 33 1.3 (0.9, 1.8) 0.2
Sodium serum <137 mmol l−1 (%) 17 28 1.7 (1.2, 2.5) 0.005
GFR <40 ml min−1 (%) 46 62 1.9 (1.4, 2.7) <0.001
Medication at discharge (%)
ARB 11 13 1.1 (0.7, 1.9) 0.6
β-Blocker
Low dose 28 17 0.5 (0.3, 0.7) 0.001*
High dose 27 14 0.4 (0.3, 0.7) 0.001
Loop diuretic
Low dose 66 46 1.1 (0.6, 1.9) 0.8
High dose 21 44 2.8 (1.6, 5.1) 0.001
Spironolactone
Low dose 28 29 1.2 (0.8, 1.8) 0.3
High dose 10 14 1.4 (0.8, 2.3) 0.2
Digoxin 22 28 1.3 (0.9, 1.9) 0.2
Antiarrhythmic 22 30 1.4 (0.9, 1.9) 0.09
Nitrates 49 51 1.1 (0.8, 1.5) 0.6
Calcium-channel blockers 13 15 1.1 (0.6, 1.7) 0.8
Coumarinic 55 60 1.2 (0.9, 1.6) 0.3
Aspirin 32 23 0.7 (0.5, 0.9) 0.04
*The reference value for all classes of medication with doses was medication not dispensed. NYHA, New York Heart Association;
LVEF, left ventricular ejection fraction; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; ARB,
angiotensin receptor blocker. A low dose of β-blocker is defined as <50% of the target dose attained in randomized clinical
trials. A low dose of loop diuretics is defined as furosemide ≤80 mg, bumetanide ≤2 mg. A low dose of spironolactone is defined
as ≤25 mg.
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(results not shown). The majority of patients were
treated with a β-blocker tested in clinical trials
(carvedilol, metoprolol or bisoprolol). No significant
differences in the type of β-blocker prescribed in
patients older and younger than 75 years were seen,
although older patients were prescribed less carvedilol
(Table 5).
Table 6 shows the relative risk reduction associated
with prescription of a β-blocker, at different ages. The
data show a linear trend within the range of 65–85 years,
which includes most of our patients. While in a patient
of 65 years the risk reduction is about 70%, in a patient
of 75 years it is 50% and in a patient of 80 years about
40%.
Discussion
In this daily practice cohort of advanced CHF patients,
prescription of a β-blocker was associated with a 45%
relative mortality risk reduction. The risk reduction
decreased with age from 71% in patients ≤75 years to
21% in the older ones.
Our findings in advanced CHF patients are consistent
with those of the SENIORS trial, which documented the
benefit of β-blocker nebivolol in elderly patients (age
>70 years) with moderate to advanced CHF [9]. The
study showed that addition of nebivolol to conventional
treatment was associated with a 12% relative risk reduc-
tion, a lesser degree of benefit, compared with that
reported in younger patients with CHF and depressed
EF (30% risk reduction). The risk reduction with β-
blockers in our cohort was slightly higher than that
reported in SENIORS, probably as a result of the higher
mortality in our study, which enrolled unselected
patients with advanced CHF.
Our results are also similar to those of a previous
Variable N (%)
Adjusted
HR 95% CI P-value
β-Blockers† 308 (49) 0.55 0.39, 0.78 0.001
β-Blockers
Age ≤75 years 140 (46) 0.29 0.16, 0.53 <0.001
Age >75 years 168 (54) 0.79 0.52, 1.20 0.3
Loop diuretics
Not prescribed 75 (12) 1.00 – –
Low dose 382 (61) 1.14 0.64, 2.04 0.6
High dose 168 (27) 1.95 1.05, 3.61 0.03
Gender (female) 292 (47) 0.67 0.47, 0.95 0.02
GFR < 40 ml min−1 300 (48) 2.08 1.47, 2.94 <0.001
Mean arterial pressure 625 (100) 0.99 0.98, 0.99 0.007
*Adjusted for age, gender, New York Heart Association class, ejection fraction,
chronic obstructive pulmonary disease, hypertension, sodium serum, concomitant
medication, and propensity scores for β-blocker use. †β-Blocker effect in the whole
population; prescription coded as yes/no, as prescription of high or low doses of
β-blocker was associated with a similar reduction in the risk of death. GFR,
Glomerular filtration rate.
Table 4
Multivariate relationship between clinical 
variables, medication use and all-cause 
mortality*
Table 5









Carvedilol 129 (41.9) 64 (45.7) 65 (38.7)
Metoprolol
succinate
84 (27.3) 39 (27.9) 45 (26.8)
Metoprolol tartrat 52 (16.9) 21 (15.0) 31 (18.5)
Bisoprolol 33 (10.7) 11 (7.9) 22 (13.1)
Atenolol 7 (2.3) 3 (2.1) 4 (2.4)
Labetalol 1 (0.3) 1 (0.7) –
Nebivolol 1 (0.3) – 1 (0.6)
Propranolol 1 (0.3) 1 (0.7) –
Data are presented as n (%). *All the population of
patients who received a β-blocker. P-value age ≤75 vs.
age >75 years nonsignificant for all types of β-blocker.
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population-based cohort study in patients with moderate
to advanced CHF; patients who received low-dose β-
blocker therapy (<50% of trial dose) had a similar
survival to those receiving higher doses [7]. A similar
benefit on survival with dispensing of low- or high-dose
β-blocker therapy has been also reported in the MERIT-
HF trial [15].
Although the overall effect on mortality observed
with β-blockers in our population was similar to that
observed in previous cohort studies [7, 11], the effect
modification by age has not been reported before. Inclu-
sion of patients with advanced CHF, as well as adjust-
ment for doses of a broad range of CHF medication,
may explain the different age-related effect observed in
our population.
The reduced benefit of β-blocker therapy in the elderly
may have several explanations. First, this group had a
significantly higher prevalence of preserved EF. In
patients with CHF and preserved EF, autonomic function
and neurohormonal activation are less severely affected
[16–18]. A previous study in the SOLVD registry has
shown that patients with EF <45% have higher levels of
plasma norepinephrine and atrial natriuretic peptides
compared with those with EF >45% [19]. Conversely,
another study reported similar concentrations of plasma
norepinephrine, but also higher concentrations of brain
and atrial natriuretic peptides in patients with systolic
HF compared with those with diastolic dysfunction [16].
Sympathetic nervous system activation in CHF is a
major contributor to the disease, and β-blockers benefit
primarily via antagonism of its effects [20, 21]. β-
blockers may also benefit via reduction in heart rate and
blood pressure, as well as reduction of arrhythmias [22].
It is possible that a lower sympathetic activation in the
CHF with preserved EF may partly explain a lesser
degree of benefit from β-blocker therapy.
Second, a decreased response to β-blocker therapy
may occur in the elderly [23–25]. Altered drug actions
in older people are mainly attributed to age-related phar-
macodynamic changes, such as alterations in receptor
density and sensitivity, endocrine activation and changes
in the autonomic nervous system. Such changes appear
in particular after the age of 70. However, a previous
meta-analysis in patients with systolic HF has shown
that older patients (>60–70 years) derive as much ben-
efit from β-blockers as those that are younger [26].
Nevertheless, exclusion of patients >75–80 years old
from the clinical trials may account for the nonsignifi-
cant difference, as a 10% lower relative risk reduction
in older patients compared with the younger ones was
reported.
Third, older patients had a higher prevalence of AF
and associated comorbidities. Retrospective analysis in
the CIBIS II study showed no survival benefit of biso-
prolol in CHF patients with poor systolic function and
AF, unlike those in sinus rhythm [27]. Some other stud-
ies have debated that β-blockers may have less effect on
symptoms and exercise capacity in patients with CHF
and AF when compared with those in sinus rhythm [28].
Finally, it may be that the increased risk of dying from
multiple causes (including biological age) in the elderly
compete with a potential benefit of β-blocker medica-
tion. That is, a patient of 80 years may have a life
expectancy of 5 years, so that the medication cannot
achieve the same benefit as in a 10 years younger
patient. Age itself may therefore be considered a con-
founder, although in our population age was not an
independent predictor of mortality.
After adjustment, prescription of loop diuretics in
high dose remained independently associated with an
increased risk of death. The deleterious effects of loop
diuretics are mainly explained through K+ excretion-
related complications and activation of the renin–
angiotensin–aldosterone system, as a result of volume
depletion [29, 30].
Our study examined clinical issues for which existing
clinical trials do not provide guidance. First, the results
indicate a beneficial effect of β-blockers on mortality in
patients with advanced CHF. The NNT shows the high
effectiveness of the treatment, with only 20 patients
necessary to treat for 6 months to avoid one event. The
beneficial effects of β-blockers appear to be higher in
patients <80 years old. Interventions must be therefore
Table 6
Relative reduction of mortality associated with prescription 





65 0.31 0.15, 0.64
70 0.38 0.20, 0.71
75 0.47 0.26, 0.83
80 0.57 0.32, 1.02
85 0.70 0.37, 1.34
*Adjusted for gender, New York Heart Association class,
ejection fraction, mean arterial pressure, chronic obstruc-
tive pulmonary disease, sodium serum, glomerular filtra-
tion rate, concomitant medication and propensity scores
for β-blocker use.
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conducted to improve prescription of β-blockers in this
age group, as the actual prescription rate (about 50%) is
much less than optimal. In older patients, prescription
of β-blockers may also deserve consideration. Although
on average an effect on mortality in these patients is not
clear, a benefit on the composite measure of mortality
and readmission may be achieved (as shown in the
SENIORS trial). Nevertheless, more clinical trials and
observational studies are warranted to provide a clear
answer on the benefit of β-blockers on mortality in eld-
erly patients with advanced CHF. Second, our study
provides information on the benefit of low-dose β-
blocker therapy. This may encourage clinicians to pre-
scribe low doses of β-blockers when high doses cannot
be achieved.
Our study has a number of limitations. First, because
β-blocker treatment was not randomized, other risk fac-
tors may have played a role. To address this issue, we
adjusted for many variables and used statistical tech-
niques to minimize selection bias. Second, cardiovascu-
lar and not overall mortality may be a more relevant
end-point in the elderly, who are at high risk of death
from multiple causes. Nevertheless, a distinction be-
tween cardiovascular and noncardiovascular causes of
death in elderly patients with CHF is in many instances
difficult. Third, we assumed that medication prescribed
at discharge was constant during follow-up. Prior stud-
ies have shown that patients discharged without a pre-
scription of a β-blocker or ACEI are unlikely to be
started on these therapies as outpatients [31, 32]. How-
ever, in patients who are discharged on these therapies,
there is a decline in use after discharge. If this is the
case, the effect of β-blockers in our study might be
overestimated, although we think not to a great extent.
To account for a potential change in medication during
follow-up readmissions, we performed the analysis
without readmitted patients (17% of the total popula-
tion) and the results were similar.
In conclusion, in this cohort of patients with advanced
CHF in daily practice, prescription of a β-blocker was
associated with a significant reduction in mortality.
However, the beneficial effects of β-blockers appear to
be greater in younger patients.
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